These fusions, such as RUNX1-RUNX1T1 and KMT2A rearrangements, are key diagnostic markers and are incorporated into contemporary AML classification systems, including WHO, ELN, and ICC, for risk stratification and treatment guidance. Here, KMT2A is linked to acute myeloid leukemia.